The increasing pace of advances in cardiology throughout the last few decades has fundamentally altered the natural course of heart patients. In the last few years, available therapies have been revolutionized completely by new transcatheter therapeutic approaches, novel ventricular assist devices, and new drugs. Also, molecular biology and genetics have a rapidly growing impact on cardiovascular diseases, enabling the field of regenerative medicine to become increasingly closer to routine clinical implementation.
Emerging Technologies for Heart Diseases was conceived to cover the recent extensive literature on current and novel therapeutic options for cardiac patients. The first volume is dedicated to heart failure and valvular disorders, and the second covers myocardial ischemia and arrhythmias. The clinical topic is addressed in several chapters divided according to the therapeutic approach (mechanical or electrical device-based, or cell and gene-based). Each of the 46 chapters focuses on clinically available solutions, new therapies currently under evaluation in clinical trials, promising preclinical technologies, and emerging concepts and innovations that have not yet been tested in a preclinical model. Also, the book discusses future challenges and opportunities for clinical implementation. Lessons learned from abandoned experimental practices are also covered, giving the readers the widest possible perspective of current therapeutic dilemmas.
Overall, this textbook was designed for physicians who want to stay up-to-date with current therapies and those of the future, for biomedical companies, and for those who wish to broaden their knowledge of new cardiovascular therapeutic options.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
SECTION 1: Treatment of heart failure device-based therapies and monitoring modalities 1. Keeping a Finger on the Pulse A brief history of cardiovascular medicine 2. Artificial mechanical hearts and ventricular assist devices 3. Percutaneous left and right ventricular support devices 4. Cardiac resynchronization therapy 5. Left atrial decompression devices 6. Device-based treatment for diastolic heart failure 7. Ultrafiltration and other treatments of volume overload in congestive heart failure 8. Cardiac physical remodeling and percutaneous solutions for the treatment of advanced Heart Failure
SECTION 2: Treatment of systolic heart failure cell and gene-based therapies, tissue engineering and biopolymers 9. Cardiac xenotransplantation 10. Marrow-derived stromal cells for cardiac regeneration 11. Heart-derived cells for therapeutic application 12. Human Pluripotent Stem Cells for Cardiac Regeneration 13. Heart Regeneration Using Somatic Cells 14. In-vitro engineered heart tissue grafts 15. Decellularization of whole hearts for cardiac regeneration 16. Gene and protein-based therapies for improving cardiac performance and regeneration 17. Biopolymers in the treatment of heart failure and cardiac remodeling
SECTION 3: Treatment of systolic heart failure novel pharmacological treatments 18. Novel pharmacotherapies for the treatment of heart failure
SECTION 4: Treatment of valvular disorders 19. Heart Valve Tissue Engineering: Current Preclinical and Clinical approaches 20. Transcatheter aortic valve replacement 21. Transcatheter mitral valve repairs for degenerative and Functional mitral regurgitation 22. Transcatheter mitral valve implantation 23. Transcatheter treatments for tricuspid valve diseases
Authors
Udi Nussinovitch Applicative Cardiovascular Research Center (ACRC) and Department of Cardiology, Meir Medical Center, affiliated to Tel Aviv University, Israel. Udi Nussinovitch, MD, PhD graduated from the Sackler Faculty of Medicine, Tel Aviv University, training at the Sheba Medical Center, Rambam Healthcare Center and Meir Medical Center, while concurrently graduating with a PhD in cardiac electrophysiology from the Technion Institute of Technology, Israel.Dr Nussinovitch has dedicated his research to investigating novel therapeutic approaches for cardiac disorders and the modulation of the cardiac electrophysiologic substrate for therapeutic purposes. He serves as director of the Applicative Cardiovascular Research Center (ACRC), affiliated to Tel Aviv University.
Dr Nussinovitch founded several biotech companies, and has been the recipient of several research awards. He carries out his clinical work at the Meir Medical Center, a medical facility and leading referral center in Israel.
